Nektar Therapeutics (NKTR) Interest & Investment Income (2010 - 2026)

Nektar Therapeutics' Interest & Investment Income history runs 9 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 47.6% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $11.8 million (down 10.25% YoY), while the FY2025 annual figure was $10.4 million, down 28.01% from the prior year.
• Interest & Investment Income was $4.2 million for Q1 2026 at Nektar Therapeutics, up from $2.8 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $5.2 million in Q3 2023 to a low of $2.0 million in Q2 2025.
• Historically, Interest & Investment Income has averaged $3.7 million across 4 years, with a median of $3.9 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Interest & Investment Income slumped 49.53% in 2025, then surged 47.6% in 2026.
• A 4-year view of Interest & Investment Income shows it stood at $4.6 million in 2023, then slumped by 36.28% to $2.9 million in 2024, then dropped by 5.64% to $2.8 million in 2025, then soared by 52.81% to $4.2 million in 2026.
• The last three Interest & Investment Income figures came in at $4.2 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.